Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | MMP1 | P03956 | 1/20 | 0.75 |
| ▸ | LDHA | P00338 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | FOS | P01100 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | JUN | P05412 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11911905 | 1.00 | CYP3A4 (0.75) | CYP3A4MMP1LDHAALOX15ALOX12 | |
| SCHEMBL18526394 | 0.92 | CYP3A4 (0.65) | CYP3A4MMP1LDHAALOX15ALOX12 | |
| SCHEMBL14221975 | 0.89 | CYP3A4 (0.61) | CYP3A4MMP1LDHAALOX15ALOX12 | |
| SCHEMBL14221354 | 0.87 | CYP3A4 (0.58) | CYP3A4MMP1LDHAALOX15ALOX12 | |
| SCHEMBL16091528 | 0.87 | CYP3A4 (0.58) | CYP3A4MMP1LDHAALOX15ALOX12 | |
| (+)-Secoisolariciresinol SCHEMBL30605875 | 0.86 | CYP3A4 (1.00) | CYP3A4MMP1ALOX15ALOX12FOS | |
| (+)-Secoisolariciresinol SCHEMBL30334899 | 0.86 | CYP3A4 (1.00) | CYP3A4MMP1ALOX15ALOX12FOS | |
| (+)-Secoisolariciresinol SCHEMBL325398 | 0.86 | CYP3A4 (1.00) | CYP3A4MMP1ALOX15ALOX12FOS | |
| (+)-Secoisolariciresinol SCHEMBL21028109 | 0.86 | CYP3A4 (1.00) | CYP3A4MMP1ALOX15ALOX12FOS | |
| (+)-Secoisolariciresinol SCHEMBL31677395 | 0.86 | CYP3A4 (1.00) | CYP3A4MMP1ALOX15ALOX12FOS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044121-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2017-02-16 | — | — | US | disclosed |
| US-9481660-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS, LLC (US) | 2016-11-01 | — | — | US | disclosed |
| US-20140221384-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2014-08-07 | — | — | US | disclosed |
| US-8691845-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS LLC (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2076125-B1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2013-12-04 | — | — | EP | disclosed |
| US-20130053378-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-8232277-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090306070-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2076125-A2 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | Erimos Pharmaceuticals LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008042921-A2 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044121-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | PTGES, HPGDS, HPGD | CYP3A4 817/4885MMP1 2635/4885LDHA 242/4885 |
| US-20090306070-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | PTGES, HPGDS, HPGD | CYP3A4 927/4885MMP1 2535/4885LDHA 266/4885 |
| US-20140221384-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE | PTGES, HPGDS, HPGD | CYP3A4 817/4885MMP1 2635/4885LDHA 242/4885 |
| US-20130053378-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | PTGES, HPGDS, HPGD | CYP3A4 927/4885MMP1 2535/4885LDHA 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.